CR20190241A - Inhibidores de magl - Google Patents

Inhibidores de magl

Info

Publication number
CR20190241A
CR20190241A CR20190241A CR20190241A CR20190241A CR 20190241 A CR20190241 A CR 20190241A CR 20190241 A CR20190241 A CR 20190241A CR 20190241 A CR20190241 A CR 20190241A CR 20190241 A CR20190241 A CR 20190241A
Authority
CR
Costa Rica
Prior art keywords
composiciones
magl
compositions
compuestos
objeto
Prior art date
Application number
CR20190241A
Other languages
English (en)
Inventor
Michael B Shaghafi
Cheryl A Grice
Daniel J Buzard
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Publication of CR20190241A publication Critical patent/CR20190241A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195Radicals derived from nitrogen analogues of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20190241A 2016-11-16 2017-11-15 Inhibidores de magl CR20190241A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423099P 2016-11-16 2016-11-16
PCT/US2017/061868 WO2018093947A1 (en) 2016-11-16 2017-11-15 Magl inhibitors

Publications (1)

Publication Number Publication Date
CR20190241A true CR20190241A (es) 2019-09-02

Family

ID=62106678

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190241A CR20190241A (es) 2016-11-16 2017-11-15 Inhibidores de magl

Country Status (29)

Country Link
US (1) US10093635B2 (es)
EP (1) EP3541821A4 (es)
JP (1) JP7042547B2 (es)
KR (1) KR20190077544A (es)
CN (1) CN110267963B (es)
AR (1) AR110089A1 (es)
AU (1) AU2017361251B2 (es)
BR (1) BR112019009994A2 (es)
CA (1) CA3043615A1 (es)
CL (1) CL2019001339A1 (es)
CO (1) CO2019005059A2 (es)
CR (1) CR20190241A (es)
DO (1) DOP2019000122A (es)
EA (1) EA038090B1 (es)
EC (1) ECSP19035077A (es)
GE (1) GEP20237470B (es)
IL (1) IL266523B (es)
JO (1) JOP20190106A1 (es)
MA (1) MA46857A (es)
MX (1) MX2019005776A (es)
NI (1) NI201900051A (es)
PE (1) PE20191144A1 (es)
PH (1) PH12019501097A1 (es)
RU (1) RU2754536C1 (es)
TN (1) TN2019000153A1 (es)
TW (1) TWI756299B (es)
UA (1) UA124542C2 (es)
WO (1) WO2018093947A1 (es)
ZA (1) ZA201903100B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107982266B (zh) 2012-01-06 2021-07-30 H.隆德贝克有限公司 氨基甲酸酯化合物及其制备和使用方法
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
PT3541807T (pt) 2016-11-16 2021-12-09 H Lundbeck As Uma forma cristalina de um inibidor de magl
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية
FI3630744T3 (fi) 2017-05-23 2023-03-21 H Lundbeck As MAGL:n pyratsoli-inhibiittoreita
MA50041A (fr) 2017-08-29 2020-07-08 Lundbeck La Jolla Research Center Inc Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
TW201946906A (zh) * 2018-05-15 2019-12-16 美商阿拜德生物製藥公司 Magl抑制劑
CN113330005A (zh) * 2019-01-25 2021-08-31 H.隆德贝克有限公司 用magl抑制剂治疗疾病的方法
CA3159391A1 (en) * 2019-11-15 2021-05-20 H. Lundbeck A/S Crystalline forms of a magl inhibitor
IT202000007150A1 (it) * 2020-04-03 2021-10-03 Univ Pisa Inibitori di monoacilglicerolo lipasi (magl)
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (es) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (en) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Plant growth inhibitor
WO1993011097A1 (en) 1991-11-27 1993-06-10 E.I. Du Pont De Nemours And Company Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives
AU1384795A (en) 1993-12-22 1995-07-10 Shell Internationale Research Maatschappij B.V. Process for preparing carbamates
AU7579696A (en) 1995-11-15 1997-06-05 Zeneca Limited Herbicidal substituted pyrazole compounds
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
EP1218544B1 (en) 1999-10-04 2009-06-03 The University of Medicine and Dentistry of New Jersey TAR RNA binding peptides
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
AU2003300702A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing carbamates
TW200531694A (en) 2004-02-18 2005-10-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
CN101830899A (zh) 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用
DK2937341T3 (en) 2004-12-30 2017-09-11 Janssen Pharmaceutica Nv 4- (BENZYL) -PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID HYDROLASE (FAAH) FOR TREATING ANALYSIS, PAIN AND OTHER CONDITIONS
EP1948630A2 (en) 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎の治療方法
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
EP2124927A2 (en) 2007-02-26 2009-12-02 Kosan Biosciences Incorporated Carbamate compounds
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
JP2011528368A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびgpcrモジュレーターとしてのその使用
JP5576874B2 (ja) 2008-11-14 2014-08-20 ザ スクリプス リサーチ インスティテュート モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物
KR20110131302A (ko) 2009-03-23 2011-12-06 엠에스디 가부시키가이샤 오로라 a 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
AU2010238732B2 (en) 2009-04-22 2015-06-11 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
CN102667934B (zh) 2009-11-03 2015-09-09 拜尔材料科学股份公司 作为光聚合物制剂中的添加剂的氟代氨基甲酸酯
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
HUE038403T2 (hu) 2012-01-06 2018-10-29 Agios Pharmaceuticals Inc Terápiásan alkalmazható vegyületek és alkalmazási módszereik
CN107982266B (zh) * 2012-01-06 2021-07-30 H.隆德贝克有限公司 氨基甲酸酯化合物及其制备和使用方法
CA2866302A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015003002A1 (en) * 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016014975A2 (en) 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
MX2017011997A (es) * 2015-03-18 2018-05-28 Abide Therapeutics Inc Carbamatos de piperacina y metodos de preparacion y uso.
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Also Published As

Publication number Publication date
MA46857A (fr) 2019-09-25
NI201900051A (es) 2019-10-30
JOP20190106A1 (ar) 2019-05-09
EA038090B1 (ru) 2021-07-05
CL2019001339A1 (es) 2019-10-04
AU2017361251B2 (en) 2021-08-19
TW201823216A (zh) 2018-07-01
DOP2019000122A (es) 2019-09-30
ZA201903100B (en) 2020-11-25
CA3043615A1 (en) 2018-05-24
EA201991073A1 (ru) 2019-12-30
US20180134674A1 (en) 2018-05-17
IL266523B (en) 2022-09-01
CN110267963B (zh) 2022-04-01
AR110089A1 (es) 2019-02-20
BR112019009994A2 (pt) 2019-08-27
UA124542C2 (uk) 2021-10-05
MX2019005776A (es) 2019-12-05
GEP20237470B (en) 2023-02-10
PE20191144A1 (es) 2019-09-02
TN2019000153A1 (en) 2020-10-05
IL266523A (en) 2019-07-31
CO2019005059A2 (es) 2019-05-31
KR20190077544A (ko) 2019-07-03
JP2020504707A (ja) 2020-02-13
RU2754536C1 (ru) 2021-09-03
WO2018093947A1 (en) 2018-05-24
RU2019116512A (ru) 2020-12-17
CN110267963A (zh) 2019-09-20
EP3541821A4 (en) 2020-04-22
US10093635B2 (en) 2018-10-09
TWI756299B (zh) 2022-03-01
NZ753264A (en) 2020-12-18
ECSP19035077A (es) 2019-05-31
EP3541821A1 (en) 2019-09-25
PH12019501097A1 (en) 2019-08-19
AU2017361251A1 (en) 2019-05-30
JP7042547B2 (ja) 2022-03-28

Similar Documents

Publication Publication Date Title
CR20190241A (es) Inhibidores de magl
CR20190243A (es) Inhibidores de magl
NI202000080A (es) Inhibidores de magl
ECSP19083923A (es) Inhibidores pirazólicos de magl
NI201900049A (es) Inhibidores de la magl
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
ECSP19084085A (es) Inhibidores pirazólicos de magl
CL2019002583A1 (es) Inhibidores duales de magl y faah.